Related Experiment Video
Updated: Mar 7, 2026
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Hepatitis C in Cameroon: What is the progress from 2001 to 2016?
Borris Rosnay Tietcheu Galani1, Richard Njouom2, Paul Fewou Moundipa3
1Laboratory of Applied Biochemistry, Department of Biological Sciences, Faculty of Science, University of Ngaoundere, PO Box 454 Ngaoundere, Ngaoundere, Cameroon, Cameroon; Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University of Yaoundé I, Yaoundé, Cameroon.
Hepatitis C virus (HCV) infection in Cameroon shows a low prevalence of 1.1%, with specific risk groups identified. Further research is needed on medicinal plants for potential hepatitis C therapy.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Chronic hepatitis C is a significant public health issue in sub-Saharan Africa, with Cameroon reporting a 7.6% prevalence in the 55-59 age group.
- Previous research has defined national seroprevalence, patient profiles, and identified potential medicinal plants for hepatitis C therapy.
- A comprehensive overview of hepatitis C research in Cameroon, integrating epidemiological, virological, and therapeutic aspects, is currently lacking.
Purpose of the Study:
- To review major findings on hepatitis C epidemiology and treatment in Cameroonian patients since 2001.
- To highlight advancements in understanding hepatitis C in Cameroon.
- To identify remaining challenges in controlling hepatitis C infection.
Main Methods:
- Systematic literature search conducted on PubMed and Google Scholar.
- Inclusion of studies focusing on prevalence, treatment, coinfection, and genetic diversity of Hepatitis C Virus (HCV) in Cameroon.
- Analysis of published data to synthesize current knowledge.
Main Results:
- HCV prevalence in Cameroon is estimated at 1.1%, with significant regional and age-related disparities.
- Identified high-risk groups include the elderly, pregnant women, blood donors, healthcare workers, hemodialysis patients, and individuals with sickle cell disease.
- Hepatitis C Virus/Hepatitis B Virus (HCV/HBV) coinfection is more prevalent than HCV/HIV coinfection.
- Genotypes 1, 2, and 4 of HCV are circulating, with limited knowledge regarding Cameroonian medicinal plants for antiviral therapy.
Conclusions:
- Epidemiological data on hepatitis C in Cameroon are relatively well-established.
- Continued efforts are essential for the prevention and control of hepatitis C infection in the region.
- Further investigation into antiviral properties of Cameroonian medicinal plants is warranted.
